Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cat allergy immunotherapy - Circassia

Drug Profile

Cat allergy immunotherapy - Circassia

Alternative Names: Cat allergen vaccine - Circassia; Cat peptide allergen desensitisation; Cat Synthetic Peptide Immuno-Regulatory Epitopes; Cat-PAD; Cat-SPIRE; ToleroMune; ToleroMune Cat

Latest Information Update: 13 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Circassia
  • Class Allergens; Antiallergics; Cat allergy immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Allergic rhinoconjunctivitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 18 Jul 2018 National Institute of Allergy and Infectious Diseases and Circassia completes a phase II trial for Allergic rhinoconjunctivitis (cat allergy) in Canada (NCT02311413)
  • 24 Jun 2018 Biomarkers information updated
  • 30 Aug 2017 Circassia completes a phase III follow-on trial for Allergic rhinoconjunctivitis in USA, Canada, Belgium, Czech Republic, Germany, Hungary, Poland, Slovakia and Russia (NCT02040844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top